BeneHold™ CHG Antimicrobial Adhesive Technology

Chlorhexidine Gluconate (CHG) is a widely recognized and accepted antimicrobial agent used in various products, including coated central venous catheters, skin antiseptics and IV site dressings.

BeneHold™ CHG adhesive technology by Vancive Medical Technologies™ delivers the functionality of this antimicrobial agent in a thin, acrylic adhesive layer. This novel adhesive technology has two granted patents and a number of others pending. The adhesive is currently designed to address needs associated with applications that require longer wear time with sustained antimicrobial efficacy (up to 7 days), but can be modified to address multiple applications each with their unique set of performance requirements.

BeneHold CHG adhesive technology is currently featured in several commercialized products:

Mechanism of Action

BeneHold™ CHG features a unique acrylic-based adhesive with four important functionalities:

CHG Mechanism of Action
  1. Has the ability to wick away fluids from the site.

  2. Has absorptive properties to manage fluids such as blood, perspiration or other exudate, and in fact, laboratory tests demonstrated that BeneHold CHG has a high fluid handling capacity comparable to that of a 0.6mm thick commercial hydrocolloid.1

  3. Is transparent allowing for visibility and monitoring of site conditions.

  4. Provides an antimicrobial effect to minimize microbial contamination and colonization of the dressing. In vitro testing (kill time and log reduction) demonstrated that the dressings have an antimicrobial effect against a variety of gram-negative, gram-positive bacteria and yeast.1

*In vitro testing shows that the transparent film of the BeneHold™ Post-Op Dressing with CHG provides a barrier to viruses 27 nm in diameter or larger if the dressing remains intact. These results have not been studied with regard to prevention of viral infection. No clinical study has been conducted regarding the ability of the dressing to prevent viral infections.

How does it work?

CHG molecules are positively charged and strongly bind to negatively charged bacterial cell walls causing damage to the bacteria’s surface structure leading to an osmotic imbalance with consequent precipitation of cytoplasm causing cell death.2

Vascular Access 

BD ChloraShield™ IV dressing with CHG Antimicrobial

The innovative BD ChloraShield IV dressing with CHG antimicrobial is designed to uniquely address some of the limitations of standard IV catheter dressings including loss of adhesive integrity due to the presence of moisture and exudate.4


The acrylic adhesive is formulated with CHG, which acts as a dressing preservative, and has been shown to sustain antimicrobial activity against skin flora for up to seven days.3


To learn more visit


Post-Operative Dressings

ReliaTect® Post-Op Dressing with CHG

ReliaTect is a sterile, post-op dressing consisting of a polyurethane film coated with BeneHold™ CHG adhesive technology, a transparent CHG acrylic adhesive developed by Vancive Medical Technologies. The non-woven border facilitates dressing application and provides additional securement during wear. ReliaTect provides the unique combination of CHG’s antimicrobial activity, transparency and absorbency.


To learn more visit


BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to better diagnose disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit

Eloquest Healthcare, Inc. is a wholly owned subsidiary of Ferndale Pharma Group, Inc. that is focused specifically on serving hospitals, their healthcare practitioners, and patients. Eloquest Healthcare helps deliver safer, more compassionate care by providing intuitive, cost-effective solutions that complement treatment protocols. More information can be found at


We see possibilities for this technology across many other medical applications including negative pressure wound therapy drapes, and acute and chronic wound care dressings. We are actively seeking partnership opportunities for new applications and geographies.

For more information on partnership opportunities, please submit your information in the form below. Our team will reach out to you to discuss the opportunity further.

Avery Dennison needs this personal information to follow-up on your request. We use your personal information for this purpose and for any other purposes set out in our Privacy Notice. By providing us with this information, you confirm that you have read and accepted our Privacy Notice.


  1. Data on file with Avery Dennison.

  2. Denton, Graham. “Chlorhexidine.” In Block, S., editor. Disinfection, Sterilization and Preservation, 5th edition. Philadelphia: Lippincott, Williams & Wilkins, 2001, 321-336.

  3. Carty, N., Wibaux, A., Ward, C., Paulson, D., and Johnson, P. “Antimicrobial activity of a novel adhesive containing chlorhexidine gluconate (CHG) against the resident microflora in human volunteers.” J Antimicrob Chemother, 2014, 69(8):2224-2229.

  4. Rickard CM, Webster J, Wallis MC, et al. Routine versus clinically indicated replacement of peripheral intravenous catheters: a randomised controlled equivalence trial. Lancet. 2012;380(9847):1066-1074. doi: 10.1016/S0140-6736(12)61082-4.